Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01736059 · ClinicalTrials.gov registry record · Phase 1
Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
A Phase 1 study of Diabetic Retinopathy and Retinitis Pigmentosa, sponsored by University of California, Davis.
- Active
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01736059 is a Phase 1 study of Diabetic Retinopathy and Retinitis Pigmentosa that is active but no longer recruiting, run by University of California, Davis. The registered enrollment target is 15 participants, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01736059, a Phase 1 study of Diabetic Retinopathy and Retinitis Pigmentosa, is active but no longer recruiting, sponsored by University of California, Davis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.
Conditions Studied
Interventions
- DRUG CD34+ bone marrow stem cells intravitreal
Study Locations (1)
California
- University of California Davis - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2012-07 |
| Est. Completion | 2026-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01736059
The ClinicalTrials.gov registry entry for NCT01736059 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,676-participant average among 57 other Diabetic Retinopathy trials with a reported enrollment target (99% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Diabetic Retinopathy appearing as the primary indexed condition, and to 1 intervention - of which CD34+ bone marrow stem cells intravitreal is the first listed.
NCT01736059 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01736059 about?
NCT01736059 is a clinical study titled "Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy". This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem cells from bone marrow into the eye as treatment for patients who are irreversibly blind from various retinal conditions.
What is the current status of trial NCT01736059?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2012-07. Estimated completion is 2026-10.
What conditions does trial NCT01736059 study?
This clinical trial studies the following conditions: Diabetic Retinopathy, Retinitis Pigmentosa, Non-exudative Age-related Macular Degeneration, Retina Vein Occlusion, Hereditary Macular Degeneration.
What interventions are being tested in trial NCT01736059?
The interventions under investigation include: CD34+ bone marrow stem cells intravitreal (DRUG).
Who is sponsoring clinical trial NCT01736059?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01736059 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)
COMPLETED · Phase 1
-
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
COMPLETED · Phase 1
-
A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers
COMPLETED · Phase 1
-
A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)
COMPLETED · Phase 1
-
Fenofibrate for Prevention of DR Worsening
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.